Capabilities
A range of expertise that turns opportunities into solutions
We provide essential capabilities to in-license a product at any stage of development
and then mobilize the resources needed to move the product toward regulatory approval
and commercialization.
A company whose commitment to excellence permeates everything we do, Forest has
been recognized for its sound business practices, including being named by Forbes
as the best managed company in the drug and biotechnology industry in 2004.
Research
Our research organization includes nearly 900 professionals with the expertise needed
to complete all phases of drug development – from investigating the therapeutic
potential and safety of early-stage molecules to conducting the clinical trial research
needed to bring important therapies such as
Lexapro® (escitalopram oxalate) and
Namenda® (memantine HCl) to the U.S. market. Our licensing strategy
and research capabilities have given us a growing and diverse pipeline. We continue
to develop our key therapeutic franchises (central nervous system, cardiovascular
and respiratory) and have expanded our development program to include agents for
inflammation and pain.
Back to Top
Regulatory
Forest’s regulatory department has extensive experience meeting drug development
and marketing approval requirements, including Investigational New Drug/New Drug
Applications (IND/NDA) and with Quality Assurance/Quality Control (QA/QC) processes.
Since 1996, we have filed more than a dozen NDA/sNDAs. Our regulatory team has shepherded
drug submissions across a range of therapeutic areas including
Lexapro® (escitalopram oxalate) for depression
and generalized anxiety disorder,
Namenda® (memantine HCl) for moderate to severe Alzheimer’s disease,
Savella® (milnacipran HCl) for the management of fibromyalgia, and Combunox® (oxycodone HCl and
ibuprofen) for the short-term management of acute, moderate to severe pain.
Back to Top
Marketing
We have a successful track record of launching and promoting products in intensely
competitive markets in the United States. Our 2002 launch quickly established Lexapro
as one of the leading antidepressants prescribed in the United States making it
the fifth largest drug launch*. Namenda became the number two product in its category
in less than three months after its 2004 launch. Benicar®
launched as the seventh ARB and has become the fastest-growing ARB. It is now third
in its class. Campral became the number one product for new prescriptions in less
than five months after its launch. Our marketing launches of Namenda, Lexapro, Benicar, Bystolic®, and Celexa®
have been recognized for marketing excellence from
various industry associations.
Back to Top
Sales Force
The Forest sales organization is comprised of 3,000 representatives in the United
States. An industry-leading sales force ranked at the top for productivity and sales
call quality, our sales forces reach primary care physicians, psychiatrists, neurologists,
cardiologists, orthopedic surgeons, pain specialists, hospitals, managed care organizations,
and senior care providers nationwide. Forest is consistently ranked as one of the
best companies to sell for by Selling Power magazine.
Back to Top
Manufacturing and Distribution
Forest manufactures pharmaceuticals in liquid and solid dosage forms using state-of-the-art
tablet and liquid production equipment. Our fully automated distribution operations
ship our products to wholesalers and distributors throughout the United States.
Back to Top
*Source: IMS NPA Plus. Based on retail TRx volume one year post launch for products
launched after June 1994
